Background And Purpose: It is currently unknown whether vaginal oestradiol is associated with development of meningioma and glioma. The aim of this study was to examine associations between cumulative use and treatment intensity of vaginally administered oestradiol tablets and incidence of meningioma and glioma in a nationwide, population-based study.
Methods: We conducted a nested case-control study within a nationwide cohort of Danish women followed from 2000 to 2018. The cohort consisted of 590,676 women aged 50-60 years at study start, without prior cancer diagnosis or use of systemic hormone therapy. Information on cumulative dose, duration, and intensity of vaginal oestradiol tablet use was assessed from filled prescriptions. Conditional logistic regression provided adjusted hazard ratios (HRs) for the association between vaginal oestradiol use and diagnosis of meningioma or glioma.
Results: We identified 1108 women with meningioma and 835 with glioma. Of these, 19.8% and 14.0% used vaginal oestradiol tablets, respectively. The HRs in those with ever-use of vaginal oestradiol tablets was 1.14 (95% confidence interval [CI] 0.97-1.34) for meningioma and 0.90 (95% CI 0.73-1.11) for glioma. The corresponding HRs for new users exclusively were 1.18 (95% CI 0.99-1.40) for meningioma and 0.89 (95% CI 0.71-1.13) for glioma. Intensity of vaginal oestradiol tablet use according to duration and user status yielded slightly elevated HRs for meningioma without an apparent dose-response pattern, while the HRs for glioma were generally below unity. Among new users, the HR with high intensity of current or recent vaginal oestradiol tablet use for 2+ years was 1.66 (95% CI 1.09-2.55) for meningioma and 0.77 (95% CI 0.41-1.44) for glioma.
Conclusion: Use of vaginal oestradiol tablets was associated with a slightly increased incidence of meningioma but not of glioma. Owing to the observational nature of the study, residual bias cannot be ruled out.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ene.15914 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Candida albicans migrates itself from the vagina to the uterus and ovaries in estrogenized mice.
Braz J Microbiol
January 2025
Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil.
Vulvovaginal candidiasis (VVC) represents the second cause of vaginal infections in childbearing-age women. It mainly affects the vulva and vagina; however, other organs can be compromised, with consequences that are not well known yet. To evaluate the ability of Candida albicans, inoculated into the vaginal lumen of mice, to migrate to the uterus and ovaries.
View Article and Find Full Text PDFReview of current and emerging estrogen receptor agonists for vaginal atrophy.
Expert Opin Pharmacother
January 2025
Femicare vzw, Tienen, Belgium.
Introduction: Vulvovaginal atrophy (VVA) predominantly affects postmenopausal women due to hormonal decline but can also occur in premenopausal women with conditions such as primary ovarian insufficiency or exposure to anti-estrogen medications. Contributing factors include smoking and certain medical treatments. Symptoms like dyspareunia and loss of sexual function affect many women but are underreported due to stigma and lack of awareness.
View Article and Find Full Text PDF[The Levels of Progesterone Receptors are Decreased in the Invasive Areas of the Recto-Vaginal Nodules of Endometriosis].
Rev Med Chil
July 2024
Departamento de Ciencias Químicas y Biológicas, Facultad de Ciencias de la Salud, Universidad Bernardo O'Higgins, Santiago, Chile.
Unlabelled: Endometriosis is a chronic disease characterized by the growth of the endometrium outside the uterine cavity. In response to estradiol, this tissue begins to proliferate and grow, forming lesions and nodules, which can invade the tissues, causing pelvic pain and infertility. The most widely used pharmacological treatment is progesterone, which manages to reduce symptoms, but approximately one-third of patients develop resistance to treatment.
View Article and Find Full Text PDFScabiosa artropurperea var.maritima aqueous extracts improve in vivo fertility parameters and in vitro granulosa cell steroidogenesis in Ewe.
Theriogenology
December 2024
CNRS, INRAE, Université de Tours, PRC, Nouzilly, France. Electronic address:
Scabiosa artropurperea, a member of the Dipsacaceae family and Scabiosa genus, is renowned for its medicinal properties. In the present study, we investigated the impact of Scabiosa artropurperea aqueous extract (AES) on the in vivo reproductive functions in Queue Fine de l'Ouest ewes, and on in vitro ovine granulosa cells. Ewes were synchronized for 14 days with intra-vagina progesterone (P4) devices (FGA, 20 mg) and divided into four groups receiving daily oral doses of 0, 1, 2, and 4 mg of AES/kg Live Body Weight (LBW), respectively.
View Article and Find Full Text PDFEffects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial.
Breast Cancer Res Treat
December 2024
Comprehensive Cancer Center, Helsinki University Hospital, University of Helsinki, PO Box 180, 00290, Helsinki, Finland.
Purpose: This study aimed to analyze changes in serum estradiol (E2) levels during concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast cancer (BC) patients with vulvovaginal atrophy (VVA). Secondary objectives included assessing the effects of therapy on vaginal atrophy, quality of life (QoL) and menopause-related symptoms.
Methods: 20 postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!